LNF2105 / Adcoris, Lunan Pharma - LARVOL DELTA

Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=294 | Not yet recruiting | Sponsor: Shandong New Time Pharmaceutical Co., LTD

New P1 trial • Oncology • Solid Tumor • NECTIN4

LNF2105, a next-generation nectin-4-targeted ADC with a specially designed linker and a DXD analogue (AACR 2026) - "Currently, only one Nectin-4 ADC with MMAE as the payload, Enfortumab Vedotin (EV), has been approved for marketing...To assess serum stability, LNF2105 and DS8201 were incubated at 37℃ for up to 25 days in human plasma; free DXD was quantified by LC/MS-MS... Overall, LNF2105 is a Nectin-4-directed ADC drug with a specially designed linker and a DXD analogue payload. Next generation site-specific conjugation technologies endow the drug with excellent homogeneity, remarkable preclinical antitumor activity, and a favorable safety profile."

ADC • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • NECTIN4